Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3-hydroxybutanoyl-CoA + an [acyl-carrier protein]
CoA + 3-hydroxybutanoyl-[acyl-carrier protein]
-
-
-
?
3-methylbutanoyl-CoA + an [acyl-carrier protein]
CoA + 3-methylbutanoyl-[acyl-carrier protein]
-
-
-
?
acetoacetyl-CoA + an [acyl-carrier protein]
CoA + acetoacetyl-[acyl-carrier protein]
-
-
-
?
acetoacetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+
a long-chain fatty acid + (n+1) CoA + n CO2 + 2n NADP+
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
acetyl-CoA + an [acyl-carrier protein]
CoA + acetyl-[acyl-carrier protein]
-
-
-
?
acetyl-CoA + malonyl-CoA + NADH
palmitate + CoA + CO2 + NAD+
-
-
-
-
?
acetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+
a long-chain fatty acid + (n+1) CoA + n CO2 + 2n NADP+
-
-
-
?
butanoyl-CoA + an [acyl-carrier protein]
CoA + butanoyl-[acyl-carrier protein]
-
-
-
?
butanoyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+
a long-chain fatty acid + (n+1) CoA + n CO2 + 2n NADP+
-
-
-
?
crotonyl-CoA + an [acyl-carrier protein]
CoA + crotonyl-[acyl-carrier protein]
-
-
-
?
malonyl-CoA + an [acyl-carrier protein]
CoA + a malonyl-[acyl-carrier protein]
-
-
-
?
methylmalonyl-CoA + an [acyl-carrier protein]
CoA + a methylmalonyl-[acyl-carrier protein]
-
-
-
?
octanoyl-CoA + an [acyl-carrier protein]
CoA + octanoyl-[acyl-carrier protein]
-
-
-
?
octanoyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+
a long-chain fatty acid + (n+1) CoA + n CO2 + 2n NADP+
-
-
-
?
palmitoyl-CoA + an [acyl-carrier protein]
CoA + palmitoyl-[acyl-carrier protein]
-
-
-
?
phenylacetyl-CoA + an [acyl-carrier protein]
CoA + phenylacetyl-[acyl-carrier protein]
-
-
-
?
succinyl-CoA + an [acyl-carrier protein]
CoA + succinyl-[acyl-carrier protein]
-
-
-
?
additional information
?
-
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity, methylmalonyl-CoA instead of malonyl-CoA yields branched fatty acid, e.g. 2,4,6,8-tetramethyldecanoic acid
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
decanoyl-CoA, acetyl-CoA, butyryl-CoA and malonyl-CoA are bound to the same active site
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
specific for malonyl-CoA, acetyl-CoA can be replaced by propionyl-CoA or butyryl-CoA
in the absence of NADPH the product is triacetic acid lactone
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
FAS-A mainly synthesizes the C18 fatty acids oleate and stearate with only traces of palmitate, the major product of FAS-B is pamitate
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
in the absence of NADPH the product is triacetic acid lactone
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
participates in energy metabolism in vivo which is related to adiposis and cancer
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
acetoacetyl-CoA can substitute for acetyl-CoA
small amounts of stearate and myristate are also produced
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
lactating mammary gland thioesterase II of fatty acid synthetase: products are medium chain fatty acids from C8 to C12, C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
-
-
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
lactating mammary gland thioesterase II of fatty acid synthetase: products are medium chain fatty acids from C8 to C12, C20 and C22 fatty acids in the absence of thioesterase activity
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
products are fatty acid chains from C14 to C20
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
-
in the absence of NADPH the product is triacetic acid lactone
?
acetyl-CoA + 7 malonyl-CoA + 14 NADPH + 14 H+
palmitate + 8 CoA + 7 CO2 + 14 NADP+ + 6 H2O
-
multifunctional enzyme, involved in animal fat synthesis
-
-
?
additional information
?
-
-
carries acetyl- and malonyl-CoA transacylase, condensing enzyme, beta-ketoacyl reductase, beta-hydroxyacyl dehydrase, enoylacyl reductase, palmitoyl-CoA thioesterase activities on each multifunctional subunit
-
-
?
additional information
?
-
-
fatty acid synthetases of vertebrates and yeast are stable enzyme complexes of multifunctional polypeptide chains, the fatty acid synthetases of plants and E. coli consist of non-associated individual enzymes
-
-
?
additional information
?
-
-
fatty acid synthase-dependent palmitoylation of epidermal growth factor receptor is required for epidermal growth factor receptor dimerization and kinase activation. Inhibition of fatty acid synthase or palmitoyl acyltransferases reduces the activity and down-regulated the levels of epidermal growth factor receptor, and sensitizes cancer cells to epidermal growth factor receptor tyrosine kinase inhibitors
-
-
?
additional information
?
-
-
enzyme generated signals are needed to support preadipocyte differentiation
-
-
?
additional information
?
-
under non-reducing conditions in the absence of NADPH, FASN produces triacetic acid lactone with an averaged malonyl consumption rate of 46 nmol per min per mg protein
-
-
-
additional information
?
-
-
fatty acid synthetases of vertebrates and yeast are stable enzyme complexes of multifunctional polypeptide chains, the fatty acid synthetases of plants and E. coli consist of non-associated individual enzymes
-
-
?
additional information
?
-
-
synthesizes equal amounts of C14 and C16 fatty acids
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-catechin
-
50% inhibition of overall enzyme reaction at 1.6 mM, 50% inhibition of ketoacyl reduction reaction at 7.4 mM
(+-)-taxifolin
-
50% inhibition at 0.041163 mM
(-)-catechin gallate
-
50% inhibition at 0.0015 mg/ml, B ring, C ring and gallate ring of inhibitor react with acyl transferase domain
(-)-epicatechin
-
50% inhibition of overall enzyme reaction at 3.8 mM, 50% inhibition of ketoacyl reduction reaction at 9.38 mM
(-)-epicatechin gallate
-
50% inhibition of overall enzyme reaction at 0.042 mM, 50% inhibition of ketoacyl reduction reaction at 0.068 mM, two-step inhibition mechanism with reversible initial inhibition and irreversible subsequent inactivation
(-)-epigallocatechin gallate
-
0.5 mM, 20% residual activity, 50% inhibition of overall enzyme reaction at 0.052 mM, 50% inhibition of ketoacyl reduction reaction at 0.1 mM
(10E,12Z)-octadec-10,12-dienoic acid
-
more potent inhibitor than (9Z,11E)-octadec-9,11-dienoic acid
(9Z,11E)-octadec-9,11-dienoic acid
-
-
1,1'-[methanediylbis(2,4,6-trihydroxy-5-methylbenzene-3,1-diyl)]dibutan-1-one
-
IC50: 0.0254 mM
1,2,3,4,6-penta-O-galloyl-beta-D-glucose
-
compound is transported across cancer cell membrane to further down-regulate FAS and activate caspase-3 in MDA-MB-231 cells. Compared with other FAS inhibitors, including catechin gallate and morin, 1,2,3,4,6-penta-O-galloyl-beta-D-glucose involves a higher reversible fast-binding inhibition with an irreversible slow-binding inhibition, i.e. saturation kinetics with a dissociation constant of 0.59 microM and a limiting rate constant of 0.16 per min. The major reacting site of PGG is on the beta-ketoacyl reduction domain of FAS. Compound exhibits different types of inhibitions against the three substrates in the FAS overall reaction
1-(2,6-dihydroxy-4-methoxy-3-methylphenyl)butan-1-one
-
IC50: 0.0491 mM
2,2'-methanediylbis(3,5-dihydroxy-4,4-dimethyl-6-propanoylcyclohexa-2,5-dien-1-one)
-
IC50: 0.0602 mM
2,3-trans-octenoyl-CoA
-
competitively inhibits malonyl-transferase reaction
2-(3-butanoyl-2,4,6-trihydroxy-5-methylbenzyl)-3,5-dihydroxy-4,4-dimethyl-6-propanoylcyclohexa-2,5-dien-1-one
-
IC50: 0.0231 mM
2-acetyl-6-(3-butanoyl-2,4,6-trihydroxy-5-methylbenzyl)-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.0287 mM
2-acetyl-6-(3-butanoyl-2,4,6-trihydroxybenzyl)-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.0297 mM
2-acetyl-6-[(2,4-dihydroxy-3,3-dimethyl-6-oxo-5-propanoylcyclohexa-1,4-dien-1-yl)methyl]-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.0717 mM
2-acetyl-6-{3-butanoyl-5-[(2,4-dihydroxy-3,3-dimethyl-6-oxo-5-propanoylcyclohexa-1,4-dien-1-yl)methyl]-2,4,6-trihydroxybenzyl}-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.031 mM
2-butanoyl-6-(3-butanoyl-2,6-dihydroxy-4-methoxy-5-methylbenzyl)-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.0326 mM
2-butanoyl-6-[(2,4-dihydroxy-3,3-dimethyl-6-oxo-5-propanoylcyclohexa-1,4-dien-1-yl)methyl]-3,5-dihydroxy-4,4-dimethylcyclohexa-2,5-dien-1-one
-
IC50: 0.0561 mM
2-[(Z)-[2-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]hydrazinylidene]methyl]pyridine
good inhibition activity against two enzyme overexpressing cancer cell lines. IC50 value for MDA-MB-468 cell 0.0083 mM, for SW-480 cell 0.0015 mM
3,4-dihydroxybenzoic acid
-
50% inhibition of overall enzyme reaction at 9.0 mM, 50% inhibition of ketoacyl reduction reaction at 30 mM
3-hydroxynaphthalen-1-yl 3,4,5-trihydroxybenzoate
analog of (-)-epigallocatechin 3-gallate. Compound displays moderate to high cytotoxicity and significantly blocks FASN activity, diminishes FASN protein expression levels and induces apoptosis
3-oxooctanoyl-CoA
-
competitively inhibits malonyl-transferase reaction
4',6,7-trihydroxylisoflavone
-
IC50: 0.0295 mM
4-hydroxynaphthalen-2-yl 3,4,5-trihydroxybenzoate
analog of (-)-epigallocatechin 3-gallate. Compound displays moderate to high cytotoxicity and significantly blocks FASN activity, diminishes FASN protein expression levels and induces apoptosis
5-chloropyrazinamide
-
IC50: 0.151 mM
adriamycin
-
cytotoxic activity against cancer cells, IC50 value for MCF-7 cell 0.0035 mM, for A-549 cell 0.0018 mM, for HL-60 cell 0.0008 mM
apigenin
-
IC50: 0.0176 mM
aryl-acyl-beta-alanyl NADP+
-
inhibits beta-ketoacyl-reductase
-
avicularin
-
IC50: 0.00615 mM
baicalein
-
50% inhibition at 0.11169 mM
Benzamide
-
100 mM, 15% inhibition
catechin gallate
-
very potent inhibitor, acts mainly on an acyl transferase domain. IC50 of 0.0015 mg/ml
catechol
-
50% inhibition of overall enzyme reaction at 7.4 mM, 50% inhibition of ketoacyl reduction reaction at 21 mM
CoA
-
competitive inhibition
crotonyl-CoA
-
dehydrase activity
daidzein
-
IC50: 0.0732 mM
diisopropylfluorophosphate
dutasteride
-
at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells
epigallocatechin-3-gallate
-
-
fisetin
-
50% inhibition at 0.01877 mM
gallic acid
-
50% inhibition of overall enzyme reaction at 21 mM, 50% inhibition of ketoacyl reduction reaction at 26 mM
grape skin extract
-
inhibits the overall reaction and beta-ketoacyl reductase reaction of FAS with IC50 values of 4.61 microg/ml and 20.3 microg/ml, respectively. Inhibits the overall reaction of FAS competitively with acetyl-CoA, noncompetitively with malonyl-CoA and in a mixed manner with NADPH
-
hesperetin
-
50% inhibition at 0.06886 mM
hyperoside
-
IC50: 0.0746 mM
iso-liquiritigenin
-
IC50: 0.0088 mM
isoquercitrin
-
IC50: 0.108 mM
long-chain acyl-CoA
-
malonyl-transferase reaction
Malonyl pantetheine
-
malonyl-transferase reaction
malonyl-CoA
-
competitive, malonyl-transferase reaction
morin
-
50% inhibition at 0.00233 mM
myricetin
-
50% inhibition at 0.02718 mM
N-ethylmaleimide
-
inhibition of elongation process and malonyl transfer at 10 mM
naphthalene-1,3-diyl bis(3,4,5-trihydroxybenzoate)
analog of (-)-epigallocatechin 3-gallate. Compound displays moderate to high cytotoxicity and significantly blocks FASN activity, diminishes FASN protein expression levels
nordihydroguaiaretic acid
-
inhibits competitively with respect to acetyl-CoA, noncompetitively with respect to malonyl-CoA, and in a mixed manner with respect toNADPH.IC50 = 0.093 mM
octanoyl-CoA
-
competitively inhibits malonyl-transferase reaction
procyanidin
-
procyanidins isolated from seeds of Hippophae rhamnoides inhibits the activity of FAS and reduces MDA-MB-231 cell viability with an IC50 value of 37.5 microg/ml. Procyanidins induce MDA-MB-231 cell apoptosis
propyl gallate
-
50% inhibition of overall enzyme reaction at 0.5 mM, 50% inhibition of ketoacyl reduction reaction at 1.4 mM
propyl p-hydroxylbenzoate
-
50% inhibition of overall enzyme reaction at 1.1 mM, 50% inhibition of ketoacyl reduction reaction at 2.6 mM
Pyrazinamide
-
IC50: 8.9 mM
quercitrin
-
IC50: 0.0456 mM
S-(4-bromo-2,3-dioxobutyl)-CoA
sodium dodecylsulfate
-
causes conformational changes at higher concentrations
tetrahydrolipstatin
-
i.e. orlistat
trans-4-carboxy-5-octyl-3-methylenebutyrolactone
-
-
Zn2+
-
80% loss of activity at 0.008 mM, interacts with SH groups, substrates of the reaction protect, malonyl-CoA being the most effective, addition of dithiothreitol leads to a recovery of 70% enzyme activity; below 0.004 mM, rapid and irreversible inactivation, above 0.004 mM, cross-linking of enzyme involving phosphopantheine SH group. All three substrates, acetyl-CoA, malonyl-CoA, NADPH, protect. Renaturation by dithiothreitol
[1,1'-biphenyl]-4,4'-diyl bis(3,4,5-trihydroxybenzoate)
analog of (-)-epigallocatechin 3-gallate. Compound displays moderate to high cytotoxicity and significantly blocks FASN activity
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
acetyl-CoA, not malonyl-CoA, protects against inactivation, both protect against cross-linking of the subunits; covalently cross-links subunits, inactivates beta-ketoacyl synthetase- and overall-fatty acid synthase reaction
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
acetyl-CoA, not malonyl-CoA, protects against inactivation, both protect against cross-linking of the subunits
1,3-Dibromo-2-propanone
-
-
1,3-Dibromo-2-propanone
-
-
C75
-
FASN inhibitor
C75
-
0.05 mM, 90% reduction of enzyme activity, dramatic reduction of visible lipid droplet accumulation, reduction of enzyme mRNA
C75
-
inactivation of beta-ketoacyl synthase, enoyl reductase and thioesterase partial activites, mechanism
C75
-
i.e. 3-carboxy-4-octyl-2-methylenebutyrolactone, 50% inhibition of enzyme at 0.2 mM
cerulenin
-
specific inhibitor
cerulenin
-
acetyl-CoA protects
cerulenin
-
IC50: 0.013 mM
cerulenin
-
significant reduction of proliferation of cell lines
cerulenin
-
0.01 mM, 75% reduction of enzyme activity, dramatic reduction of visible lipid droplet accumulation, reduction of enzyme mRNA
cerulenin
-
no inhibitory at 3 mM, 62% inhibition at 6.0 mM
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
-
galangin
-
50% inhibition above 0.1 mM
galangin
-
poor inhibition
ginkgolic acid C15:1
-
DELTA8 and DELTA10 isomers, at ratio 1:2
ginkgolic acid C15:1
-
DELTA8 and DELTA10 isomers, at ratio 1:2. Cytotoxic activity against cancer cells, IC50 value for MCF-7 cell 0.146 mM, for A-549 cell 0.066 mM, for HL-60 cell 0.005 mM
ginkgolic acid C17:1
-
double bond positions not specified
ginkgolic acid C17:1
-
double bond positions not specified. Cytotoxic activity against cancer cells, IC50 value for MCF-7 cell 0.093 mM, for A-549 cell 0.050 mM, for HL-60 cell 0.004 mM
ginkgolic acid C17:2
-
double bond positions not specified
ginkgolic acid C17:2
-
double bond positions not specified. Cytotoxic activity against cancer cells, IC50 value for MCF-7 cell 0.108 mM, for A-549 cell 0.056 mM, for HL-60 cell 0.004 mM
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
kinetics, 50% inactivation after 5 min at 1 mM and after 0.5 min at 20 mM
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
inhibits beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
beta-ketoacyl synthetase activity, acetyl-CoA but not malonyl-CoA protects
iodoacetamide
-
inhibition of elongation processs
kaempferol
-
50% inhibition at 0.01038 mM
kaempferol
-
50% inhibition at 0.00298 mg/ml
luteolin
-
50% inhibition at 0.00252 mM
luteolin
-
IC50: 0.0625 mM
PMSF
-
-
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
pyridoxal 5'-phosphate
-
enoyl reductase activity, NADPH protects
quercetin
-
50% inhibition at 0.00429 mM
quercetin
-
50% inhibition at 0.0024 mg/ml, mixed type inhibition for substrate NADPH, competitive with substrate acetyl-CoA, noncompetitive with malonyl-CoA
resveratrol
-
IC50: 0.0085 mM
resveratrol
-
inhibits the overall reaction and beta-ketoacyl reductase reaction of FAS with IC50 values of 11.1 microg/ml and 21.9 microg/ml, respectively. In 3 T3-L1 preadipocytes, resveratrol reduces lipid accumulation remarkably
S-(4-bromo-2,3-dioxobutyl)-CoA
-
irreversible, acetyl transacetylase and beta-ketoacyl synthase activity, 4 mol inhibitor per mol enzyme complex, mechanism, dithiothreitol protects
S-(4-bromo-2,3-dioxobutyl)-CoA
-
irreversible, 50% inhibition after 10 s at 0.02 mM, 6.5 s at 0.06 mM and 4.5 s at 0.09 mM, specific for acetyl transacetylase and beta-ketoacyl synthase activity, 4 mol inhibitor per mol enzyme complex, acetyl-CoA, malonyl-CoA, cysteine and pantetheine protect
triclosan
-
-
triclosan
-
0.05 mM, 70% reduction of enzyme activity, dramatic reduction of visible lipid droplet accumulation, reduction of enzyme mRNA
triclosan
-
inititation of mammary carcinogenesis is reduced in animals fed with triclosan, triclosan also inhibits enzyme activity in tumor cell homogenates
Urea
-
enzyme forms inactive aggregates in the presence of urea, cyclodextrins prevent aggregation
Urea
-
non-competitive inhibitor for NADPH, competitive inhibitor for acetyl-CoA and malonyl-CoA, complete inactivation occurs at lower concentration than obvious conformational changes, aggregation occurs at 3-4 M
additional information
-
the enzyme is potently inhibited by green tea extract
-
additional information
-
a common model is proposed that is possibly shared by all FAS polyphenol inhibitors. The model includes two almost planar aromatic rings with their respective hydroxyl groups, and a proper ester linkage between the two rings that possibly causes the inhibition of FAS by irreversibly inhibiting the beta-ketoacyl reductase domain
-
additional information
-
FAS is potently inhibited by extracts of Taxillus chinensis Danser. Potent, reversible and a fast irreversible inhibition. IC50: 480 ng/ml
-
additional information
-
not inhibitory: NAD+ or NADP+ up to 5 mM
-
additional information
-
inhibition by extract from rhizome of Alpinia officinarum, i.e. galangal. Inhibition consists of both reversible inhibition with an IC50-value of 0.0017 mg dried extract per ml, and biphasic slow-binding inactivation
-
additional information
-
black tea extract shows more potent inhibitory activity on fatty acid synthase than green tea extract. Inhibitory ability of the black tea extract depends on the extracting solvent and the conditions used. Only 1023% of the inhibitory activity from the black tea is extracted by the general method of boiling with water. The results suggest that the main fatty acid synthase inhibitors in black tea might be theaflavins
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Atherosclerosis
Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis.
Breast Neoplasms
Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Carcinoma, Hepatocellular
Human fatty acid synthase: properties and molecular cloning.
Chronic Periodontitis
Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).
Dehydration
Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone.
Dehydration
Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis.
Dehydration
The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.
fatty-acid synthase system deficiency
Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis.
Infections
A combined transcriptome and proteome survey of malaria parasite liver stages.
Infections
Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.
Infections
Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
Infections
The Staphylococcus aureus FASII bypass escape route from FASII inhibitors.
Insulin Resistance
Antiobesity efficacy of asiatic acid: down-regulation of adipogenic and inflammatory processes in high fat diet induced obese rats.
Insulin Resistance
ChREBP binding and histone modifications modulate hepatic expression of the Fasn gene in a metabolic syndrome rat model.
Insulin Resistance
Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
Malaria
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
Malaria
2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes.
Malaria
A combined transcriptome and proteome survey of malaria parasite liver stages.
Malaria
Analogues of thiolactomycin as potential antimalarial agents.
Malaria
Characterization of the Plasmodium falciparum and P. berghei glycerol 3-phosphate acyltransferase involved in FASII fatty acid utilization in the malaria parasite apicoplast.
Malaria
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase.
Malaria
Fatty acid metabolism in the Plasmodium apicoplast: Drugs, doubts and knockouts.
Malaria
Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes.
Neoplasms
4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75), an inhibitor of fatty-acid synthase, suppresses the mitochondrial fatty acid synthesis pathway and impairs mitochondrial function.
Neoplasms
Antiobesity efficacy of asiatic acid: down-regulation of adipogenic and inflammatory processes in high fat diet induced obese rats.
Neoplasms
Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines.
Neoplasms
Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.
Neoplasms
Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.
Neoplasms
Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4.
Neoplasms
Inhibitive effect of zinc ion on fatty acid synthase from chicken liver.
Neoplasms
Lipid signalling enforces functional specialization of Treg cells in tumours.
Neoplasms
Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Neoplasms
Proto-oncogene FBI-1 (Pokemon) and SREBP-1 Synergistically Activate Transcription of Fatty-acid Synthase Gene (FASN).
Neoplasms
The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase.
Neuroblastoma
Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines.
Obesity
Identification and structural characterization of an unusual mycobacterial monomeromycolyl-diacylglycerol.
Polycystic Kidney Diseases
A C. elegans model for mitochondrial fatty acid synthase II: the longevity-associated gene W09H1.5/mecr-1 encodes a 2-trans-enoyl-thioester reductase.
Prostatic Neoplasms
Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.
Retinoblastoma
Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines.
Rhabdoid Tumor
Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines.
Sepsis
Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.
Starvation
Dietary-induced pre-translational control of rat fatty acid synthase.
Toxoplasmosis
Apicoplast-Localized Lysophosphatidic Acid Precursor Assembly Is Required for Bulk Phospholipid Synthesis in Toxoplasma gondii and Relies on an Algal/Plant-Like Glycerol 3-Phosphate Acyltransferase.
Tuberculosis
A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone.
Tuberculosis
A novel interaction linking the FAS-II and phthiocerol dimycocerosate (PDIM) biosynthetic pathways.
Tuberculosis
AccD6, a key carboxyltransferase essential for mycolic acid synthesis in Mycobacterium tuberculosis, is dispensable in a nonpathogenic strain.
Tuberculosis
AccD6, a member of the Fas II locus, is a functional carboxyltransferase subunit of the acyl-coenzyme A carboxylase in Mycobacterium tuberculosis.
Tuberculosis
AcpM, the meromycolate extension acyl carrier protein of Mycobacterium tuberculosis, is activated by the 4'-phosphopantetheinyl transferase PptT, a potential target of the multistep mycolic acid biosynthesis.
Tuberculosis
Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Tuberculosis
Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA:AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II.
Tuberculosis
Characterization and site-directed mutagenesis of the putative novel acyl carrier protein Rv0033 and Rv1344 from Mycobacterium tuberculosis.
Tuberculosis
Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene.
Tuberculosis
Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone.
Tuberculosis
Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis.
Tuberculosis
Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate.
Tuberculosis
Detection and Confirmation of Alkaloids in Leaves of Justicia adhatoda and Bioinformatics Approach to Elicit Its Anti-tuberculosis Activity.
Tuberculosis
Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis.
Tuberculosis
Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli.
Tuberculosis
Expression, purification, and characterization of the Mycobacterium tuberculosis acyl carrier protein, AcpM.
Tuberculosis
Flavonoid inhibitors as novel antimycobacterial agents targeting Rv0636, a putative dehydratase enzyme involved in Mycobacterium tuberculosis fatty acid synthase II.
Tuberculosis
Function of heterologous Mycobacterium tuberculosis InhA, a type 2 fatty acid synthase enzyme involved in extending C20 fatty acids to C60-to-C90 mycolic acids, during de novo lipoic acid synthesis in Saccharomyces cerevisiae.
Tuberculosis
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
Tuberculosis
Inhibitory activity of pentacyano(isoniazid)ferrate(II), IQG-607, against promastigotes and amastigotes forms of Leishmania braziliensis.
Tuberculosis
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
Tuberculosis
Ligand-induced fit in mycobacterial MabA: the sequence-specific C-terminus locks the conformational change.
Tuberculosis
MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II.
Tuberculosis
Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis.
Tuberculosis
Physiological Function of Mycobacterial mtFabD, an Essential Malonyl-CoA:AcpM Transacylase of Type 2 Fatty Acid Synthase FASII, in Yeast mct1Delta Cells.
Tuberculosis
Point mutations within the fatty acid synthase type II dehydratase components HadA or HadC contribute to isoxyl resistance in Mycobacterium tuberculosis.
Tuberculosis
Probing reactivity and substrate specificity of both subunits of the dimeric Mycobacterium tuberculosis FabH using alkyl-CoA disulfide inhibitors and acyl-CoA substrates.
Tuberculosis
Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.
Tuberculosis
Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
Tuberculosis
Rv3080c regulates the rate of inhibition of mycobacteria by isoniazid through FabD.
Tuberculosis
The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation.
Tuberculosis
The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.
Tuberculosis
The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development.
Tuberculosis
The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes.
Tuberculosis
The new tuberculosis drug Perchlozone(®) shows cross-resistance with thiacetazone.
Tuberculosis
Triclosan inhibition of mycobacterial InhA in Saccharomyces cerevisiae: yeast mitochondria as a novel platform for in vivo antimycolate assays.
Tuberculosis
X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB).
Urinary Bladder Neoplasms
Inhibition of Fatty-acid Synthase Suppresses P-AKT and Induces Apoptosis in Bladder Cancer.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Vagelos, R.P.
Acyl group transfer (acyl carrier protein)
The Enzymes, 3rd Ed. (Boyer, P. D. , ed. )
8
155-199
1973
Columba sp., Rattus norvegicus
-
brenda
Rangan, V.S.; Smith, S.
Alteration of the substrate specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue
J. Biol. Chem.
272
11975-11978
1997
Rattus norvegicus
brenda
Rangan, V.S.; Joshi, A.K.; Smith, S.
Fatty acid synthase dimers containing catalytically active beta-ketoacyl synthase or malonyl/acetyltransferase domains in only one subunit can support fatty acid synthesis at the acyl carrier protein domains of both subunits
J. Biol. Chem.
273
34949-34953
1998
Rattus norvegicus
brenda
Puri, R.N.; Porter, J.W.
Isolation and partial purification of elastase-released peptide domains that contain the partial activities of pigeon liver fatty acid synthetase
Biochem. Biophys. Res. Commun.
107
1212-1218
1982
Columba sp.
brenda
Jenik, R.A.; Porter, J.W.
Red blood cell fatty acid synthetase. Nonidentity with the enzyme from liver
Int. J. Biochem.
10
609-617
1979
Rattus norvegicus
brenda
Stoops, J.K.; Ross, P.; Arslanian, M.J.; Aune, K.C.; Wakil, S.J.
Physicochemical studies of the rat liver and adipose fatty acid synthetases
J. Biol. Chem.
254
7418-7426
1979
Rattus norvegicus, Rattus norvegicus Sprague-Dawley
brenda
McCarthy, A.D.; Hardie, D.G.
The multifunctional polypeptide chains of rabbit-mammary fatty-acid synthase. Stoichiometry of active sites and active-site mapping using limited proteolysis
Eur. J. Biochem.
130
185-193
1983
Oryctolagus cuniculus
brenda
Katiyar, S.S.; Pan, D.; Porter, J.W.
Role of cysteine and 4-phosphopantetheine in the inactivation of pigeon liver fatty acid synthetase by S-(4-bromo-2,3-dioxobutyl)-coenzyme A
Biochem. Biophys. Res. Commun.
104
517-522
1982
Columba sp.
brenda
Katiyar, S.S.; Pan, D.; Porter, J.W.
Inactivation of 3-oxoacyl synthetase activity of pigeon liver fatty acid synthetase by S-(4-bromo-2,3-dioxobutyl)-coenzyme A
Eur. J. Biochem.
130
177-184
1983
Columba sp.
brenda
Wakil, S.J.; Stoops, J.K.; Joshi, V.C.
Fatty acid synthesis and its regulation
Annu. Rev. Biochem.
52
537-579
1983
Anser sp., Bos taurus, Canis lupus familiaris, Gallus gallus, Columba sp., Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Muesing, R.A.; Porter, J.W.
Fatty acid synthase from pigeon liver
Methods Enzymol.
35
45-49
1975
Gallus gallus, Columba sp., Rattus norvegicus
brenda
Podack, E.R.; Saathoff, G.; Seubert, W.
On the mechanism and control of the malonyl-CoA-dependent chain elongation of fatty acids. The malonyl-transfer reaction
Eur. J. Biochem.
50
237-243
1974
Rattus norvegicus
brenda
Stoops, J.K.; Wakil, S.J.
Animal fatty acid synthetase. A novel arrangement of the beta-ketoacyl synthetase sites comprising domains of the two subunits
J. Biol. Chem.
256
5128-5133
1981
Gallus gallus
brenda
Mikkelsen, J.; Hoejrup, P.; Hansen, H.F.; Hansen, J.K.; Knudsen, J.
Evidence that the medium-chain acyltransferase of lactating-goat mammary-gland fatty acid synthetase is identical with the acetyl/malonyltransferase
Biochem. J.
227
981-985
1985
Capra hircus
brenda
Wong, H.; Mattick, J.S.; Wakil, S.J.
The architecture of the animal fatty acid synthetase. III. Isolation and characterization of beta-ketoacyl reductase
J. Biol. Chem.
258
15305-15311
1983
Gallus gallus
brenda
Tsukamoto, Y.; Wong, H.; Mattick, J.S.; Wakil, S.J.
The architecture of the animal fatty acid synthetase complex. IV. Mapping of active centers and model for the mechanism of action
J. Biol. Chem.
258
15312-15322
1983
Gallus gallus
brenda
Chirala, S.S.; Huang, W.Y.; Jayakumar, A.; Sakai, K.; Wakil, S.J.
Animal fatty acid synthase: Functional mapping and cloning and expression of the domain I constituent activities
Proc. Natl. Acad. Sci. USA
94
5588-5593
1997
Gallus gallus
brenda
Foretz, M.; Foufelle, F.; Ferre, P.
Polyunsaturated fatty acids inhibit fatty acid synthase and spot-14-protein gene expression in cultured rat hepatocytes by a peroxidative mechanism
Biochem. J.
341
371-376
1999
Rattus norvegicus
-
brenda
Jayakumar, A.; Huang, W.Y.; Raetz, B.; Chirala, S.S.; Wakil, S.J.
Cloning and expression of the multifunctional human fatty acid synthase and its subdomains in Escherichia coli
Proc. Natl. Acad. Sci. USA
93
14509-14514
1996
Homo sapiens
brenda
Jayakumar, A.; Tai, M.H.; Huang, W.Y.; Al-Feel, W.; Hsu, M.; Abu-Elheiga, L.; Chirala, S.S.; Wakil, S.J.
Human fatty acid synthase: properties and molecular cloning
Proc. Natl. Acad. Sci. USA
92
8695-8699
1995
Homo sapiens
brenda
Joshi, A.K.; Rangan, V.S.; Smith, S.
Differential affinity labelling of the two subunits of the homodimeric animal fatty acid synthase allows isolation of heterodimers consisting of subunits that have been independently modified
J. Biol. Chem.
273
4937-4943
1998
Rattus norvegicus
brenda
Park, Y.D.; Wu, B.N.; Tian, W.X.; Zhou, H.M.
Effects of osmolytes on unfolding of chicken liver fatty acid synthase
Biochemistry (Moscow)
67
914-917
2002
Gallus gallus
brenda
Simpson, K.J.; Venkatesan, S.; Peters, T.J.
Fatty acid synthesis by rat liver after chronic ethanol feeding with a low-fat diet
Clin. Sci.
87
441-446
1994
Rattus norvegicus
brenda
Shi, Y.; Luo, W.; Tian, W.X.; Zhang, T.; Zhou, H.M.
Inactivation and conformational changes of fatty acid synthase from chicken liver during unfolding by sodium dodecyl sulfate
Int. J. Biochem. Cell Biol.
30
1319-1330
1998
Gallus gallus
brenda
Stuible, H.P.; Meurer, G.; Schweizer, E.
Heterologous expression and biochemical characterization of two functionally different type I fatty acid synthases from Brevibacterium ammoniagenes
Eur. J. Biochem.
247
268-273
1997
Corynebacterium ammoniagenes
brenda
Stuible, H.P.; Wagner, C.; Andreou, J.; Guter, G.; Haselmann, J.; Schweizer, E.
Identification and functional differentiation of two type I fatty acid synthases in Brevibacterium ammoniagenes
J. Bacteriol.
178
4787-4793
1996
Corynebacterium ammoniagenes
brenda
Wagle, S.; Bui, A.; Ballard, P.L.; Shuman, H.; Gonzales, J.; Gonzales, L.W.
Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung
Am. J. Physiol.
277
L381-L390
1999
Homo sapiens
brenda
Wang, F.; Wang, X.; Liu, Y.; Tian, W.X.; Zhou, H.M.
Inhibitive effect of zinc ion on fatty acid synthase from chicken liver
Int. J. Biochem. Cell Biol.
35
391-400
2003
Gallus gallus
brenda
Witkowski, A.; Joshi, S.; Smith, S.
Fatty acid synthase: in vitro complementation of inactive mutants
Biochemistry
35
10569-10575
1996
Rattus norvegicus
brenda
Wu, B.N.; Park, Y.D.; Tian, W.X.; Zhou, H.M.
Unfolding and inactivation of fatty acid synthase from chicken liver during urea denaturation
Biochim. Biophys. Acta
1549
112-121
2001
Gallus gallus
brenda
Ide, T.; Ashakumary, L.; Takahashi, Y.; Kushiro, M.; Fukuda, N.; Sugano, M.
Sesamin, a sesame lignan, decreases fatty acid synthesis in rat liver accompanying the down-regulation of sterol regulatory element binding protein-1
Biochim. Biophys. Acta
1534
1-13
2001
Rattus norvegicus
brenda
Yu, X.X.; Lewin, D.A.; Forrest, W.; Adams, S.H.
Cold elicits the simultaneous induction of fatty acid synthesis and beta-oxidation in murine brown adipose tissue: prediction from differential gene expression and confirmation in vivo
FASEB J.
16
155-168
2002
Mus musculus, Mus musculus FVB-N
brenda
Swinnen, J.V.; Van Veldhoven, P.P.; Timmermans, L.; De Schrijver, E.; Brusselmans, K.; Vanderhoydonc, F.; Van de Sande, T.; Heemers, H.; Heyns, W.; Verhoeven, G.
Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains
Biochem. Biophys. Res. Commun.
302
898-903
2003
Homo sapiens
brenda
Schmid, B.; Rippmann, J.F.; Tadayyon, M.; Hamilton, B.S.
Inhibition of fatty acid synthase prevents preadipocyte differentiation
Biochem. Biophys. Res. Commun.
328
1073-1082
2005
Mus musculus
brenda
Rendina, A.R.; Cheng, D.
Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates
Biochem. J.
388
895-903
2005
Rattus norvegicus
brenda
Wang, X.; Song, K.S.; Guo, Q.X.; Tian, W.X.
The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase
Biochem. Pharmacol.
66
2039-2047
2003
Gallus gallus
brenda
Witkowski, A.; Joshi, A.K.; Smith, S.
Characterization of the beta-carbon processing reactions of the mammalian cytosolic fatty acid synthase: role of the central core
Biochemistry
43
10458-10466
2004
Rattus norvegicus
brenda
Zhang, R.; Xiao, W.; Wang, X.; Wu, X.; Tian, W.
Novel inhibitors of fatty acid synthase from green tea with high activity and new reacting site
Biotechnol. Appl. Biochem.
43
1-7
2005
Anas platyrhynchos, Gallus gallus
brenda
Lu, S.; Archer, M.C.
Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer
Carcinogenesis
26
153-157
2005
Rattus norvegicus
brenda
Joshi, A.K.; Rangan, V.S.; Witkowski, A.; Smith, S.
Engineering of an active animal fatty acid synthase dimer with only one competent subunit
Chem. Biol.
10
169-173
2003
Rattus norvegicus
brenda
Rohrbach, K.W.; Han, S.; Gan, J.; O'Tanyi, E.J.; Zhang, H.; Chi, C.L.; Taub, R.; Largent, B.L.; Cheng, D.
Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents
Eur. J. Pharmacol.
511
31-41
2005
Rattus norvegicus
brenda
Li, B.H.; Tian, W.X.
Inhibitory effects of flavonoids on animal fatty acid synthase
J. Biochem.
135
85-91
2004
Anas platyrhynchos
brenda
Kim, H.; Choi, S.; Lee, H.J.; Lee, J.H.; Choi, H.
Suppression of fatty acid synthase by dietary polyunsaturated fatty acids is mediated by fat itself, not by peroxidative mechanism
J. Biochem. Mol. Biol.
36
258-264
2003
Rattus norvegicus
brenda
Li, B.H.; Tian, W.X.
Presence of fatty acid synthase inhibitors in the rhizome of Alpinia officinarum hance
J. Enzyme Inhib. Med. Chem.
18
349-356
2003
Gallus gallus
brenda
Asturias, F.J.; Chadick, J.Z.; Cheung, I.K.; Stark, H.; Witkowski, A.; Joshi, A.K.; Smith, S.
Structure and molecular organization of mammalian fatty acid synthase
Nat. Struct. Mol. Biol.
12
225-232
2005
Rattus norvegicus
brenda
Agostini, M.; Silva, S.D.; Zecchin, K.G.; Coletta, R.D.; Jorge, J.; Loda, M.; Graner, E.
Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells
Oral Oncol.
40
728-735
2004
Homo sapiens
brenda
Chirala, S.S.; Chang, H.; Matzuk, M.; Abu-Elheiga, L.; Mao, J.; Mahon, K.; Finegold, M.; Wakil, S.J.
Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero
Proc. Natl. Acad. Sci. USA
100
6358-6363
2003
Mus musculus
brenda
Chakravarty, B.; Gu, Z.; Chirala, S.S.; Wakil, S.J.; Quiocho, F.A.
Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain
Proc. Natl. Acad. Sci. USA
101
15567-15572
2004
Homo sapiens (P49327)
brenda
Pflug, B.R.; Pecher, S.M.; Brink, A.W.; Nelson, J.B.; Foster, B.A.
Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model
Prostate
57
245-254
2003
Mus musculus
brenda
Carlisle-Moore, L.; Gordon, C.R.; Machutta, C.A.; Miller, W.T.; Tonge, P.J.
Substrate recognition by the human fatty-acid synthase
J. Biol. Chem.
280
42612-42618
2005
Homo sapiens
brenda
Asturias, F.J.
Mammalian fatty acid synthase: X-ray structure of a molecular assembly line
ACS Chem. Biol.
1
135-138
2006
Homo sapiens
brenda
Consolazio, A.; Alo, P.L.; Rivera, M.; Iacopini, F.; Paoluzi, O.A.; Crispino, P.; Pica, R.; Paoluzi, P.
Overexpression of fatty acid synthase in ulcerative colitis
Am. J. Clin. Pathol.
126
113-118
2006
Homo sapiens
brenda
Ngo, S.C.; Zimhony, O.; Chung, W.J.; Sayahi, H.; Jacobs, W.R.; Welch, J.T.
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs
Antimicrob. Agents Chemother.
51
2430-2435
2007
Mycobacterium tuberculosis
brenda
Na, M.; Jang, J.; Min, B.S.; Lee, S.J.; Lee, M.S.; Kim, B.Y.; Oh, W.K.; Ahn, J.S.
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma
Bioorg. Med. Chem. Lett.
16
4738-4742
2006
Gallus gallus
brenda
Najjar, S.M.; Yang, Y.; Fernstroem, M.A.; Lee, S.J.; Deangelis, A.M.; Rjaily, G.A.; Al-Share, Q.Y.; Dai, T.; Miller, T.A.; Ratnam, S.; Ruch, R.J.; Smith, S.; Lin, S.H.; Beauchemin, N.; Oyarce, A.M.
Insulin acutely decreases hepatic fatty acid synthase activity
Cell Metab.
2
43-53
2005
Mus musculus
brenda
Lupu, R.; Menendez, J.A.
Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Curr. Pharm. Biotechnol.
7
483-494
2006
Homo sapiens
brenda
Li, B.H.; Ma, X.F.; Wang, Y.; Tian, W.X.
Structure-activity relationship of polyphenols that inhibit fatty acid synthase
J. Biochem.
138
679-685
2005
Anas platyrhynchos
brenda
Molle, V.; Brown, A.K.; Besra, G.S.; Cozzone, A.J.; Kremer, L.
The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation
J. Biol. Chem.
281
30094-30103
2006
Mycobacterium tuberculosis
brenda
Du, Y.T.; Wang, X.; Wu, X.D.; Tian, W.X.
Keemun black tea extract contains potent fatty acid synthase inhibitors and reduces food intake and body weight of rats via oral administration
J. Enzyme Inhib. Med. Chem.
20
349-356
2005
Rattus norvegicus
brenda
Wang, Y.; Zhang, S.Y.; Ma, X.F.; Tian, W.X.
Potent inhibition of fatty acid synthase by parasitic loranthus [Taxillus chinensis (dc.) danser] and its constituent avicularin
J. Enzyme Inhib. Med. Chem.
21
87-93
2006
Anas platyrhynchos
brenda
Matsukuma, K.E.; Bennett, M.K.; Huang, J.; Wang, L.; Gil, G.; Osborne, T.F.
Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase
J. Lipid Res.
47
2754-2761
2006
Mus musculus
brenda
van de Sande, T.; Roskams, T.; Lerut, E.; Joniau, S.; Van Poppel, H.; Verhoeven, G.; Swinnen, J.V.
High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB
J. Pathol.
206
214-219
2005
Homo sapiens
brenda
Wang, H.Q.; Altomare, D.A.; Skele, K.L.; Poulikakos, P.I.; Kuhajda, F.P.; Di Cristofano, A.; Testa, J.R.
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells
Oncogene
24
3574-3582
2005
Homo sapiens
brenda
Schmidt, L.J.; Ballman, K.V.; Tindall, D.J.
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride
Prostate
67
1111-1120
2007
Homo sapiens
brenda
Maier, T.; Jenni, S.; Ban, N.
Architecture of mammalian fatty acid synthase at 4.5 A resolution
Science
311
1258-1262
2006
Sus scrofa
brenda
Grunt, T.W.; Wagner, R.; Grusch, M.; Berger, W.; Singer, C.F.; Marian, B.; Zielinski, C.C.; Lupu, R.
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells
Biochem. Biophys. Res. Commun.
385
454-459
2009
Homo sapiens
brenda
Kim, K.J.; Kim, H.Y.; Cho, H.K.; Kim, K.H.; Cheong, J.
The SDF-1alpha/CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element binding protein-1 activation in cancer cells
Carcinogenesis
31
679-686
2010
Homo sapiens
brenda
Gurvitz, A.
A novel circuit overrides Adr1p control during expression of Saccharomyces cerevisiae 2-trans-enoyl-ACP reductase Etr1p of mitochondrial type 2 fatty acid synthase
FEMS Microbiol. Lett.
297
255-260
2009
Saccharomyces cerevisiae
brenda
Lu, S.; Archer, M.C.
Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells
Int. J. Cancer
126
416-425
2010
Homo sapiens
brenda
Duckett, S.K.; Pratt, S.L.; Pavan, E.
Corn oil or corn grain supplementation to steers grazing endophyte-free tall fescue. II. Effects on subcutaneous fatty acid content and lipogenic gene expression
J. Anim. Sci.
87
1120-1128
2009
Bos taurus
brenda
Gurvitz, A.
Caenorhabditis elegans F09E10.3 encodes a putative 3-oxoacyl-thioester reductase of mitochondrial type 2 fatty acid synthase FASII that is functional in yeast
J. Biomed. Biotechnol.
2009
235868
2009
Caenorhabditis elegans
brenda
Crescenzo, R.; Bianco, F.; Falcone, I.; Prisco, M.; Dulloo, A.G.; Liverini, G.; Iossa, S.
Hepatic mitochondrial energetics during catch-up fat after caloric restriction
Metabolism
59
1221-1230
2010
Rattus norvegicus
brenda
Gurvitz, A.
The essential mycobacterial genes, fabG1 and fabG4, encode 3-oxoacyl-thioester reductases that are functional in yeast mitochondrial fatty acid synthase type 2
Mol. Genet. Genomics
282
407-416
2009
Mycobacterium tuberculosis
brenda
Choi, J.S.; Kim, H.; Jung, M.H.; Hong, S.; Song, J.
Consumption of barley beta-glucan ameliorates fatty liver and insulin resistance in mice fed a high-fat diet
Mol. Nutr. Food Res.
54
1004-1013
2010
Mus musculus
brenda
Lau, D.S.; Archer, M.C.
The 10t,12c isomer of conjugated linoleic acid inhibits fatty acid synthase expression and enzyme activity in human breast, colon, and prostate cancer cells
Nutr. Cancer
62
116-121
2010
Homo sapiens
brenda
Chen, Q.; Reimer, R.A.
Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro
Nutrition
25
340-349
2009
Homo sapiens
brenda
Fujimoto, T.; Miyasaka, K.; Koyanagi, M.; Tsunoda, T.; Baba, I.; Doi, K.; Ohta, M.; Kato, N.; Sasazuki, T.; Shirasawa, S.
Altered energy homeostasis and resistance to diet-induced obesity in KRAP-deficient mice
PLoS One
4
e4240
2009
Mus musculus
brenda
Gurvitz, A.
A C. elegans model for mitochondrial fatty acid synthase II: the longevity-associated gene W09H1.5/mecr-1 encodes a 2-trans-enoyl-thioester reductase
PLoS ONE
4
e7791
2009
Caenorhabditis elegans
brenda
Nguyen, L.N.; Trofa, D.; Nosanchuk, J.D.
Fatty acid synthase impacts the pathobiology of Candida parapsilosis in vitro and during mammalian infection
PLoS ONE
4
e8421
2009
Candida parapsilosis
brenda
Antelo, L.; Schlipp, A.; Hof, C.; Eisfeld, K.; Berg, H.; Hornbogen, T.; Zocher, R.; Anke, H.
The fatty acid synthase of the basidiomycete Omphalotus olearius is a single polypeptide
Z. Naturforsch. C
64
244-250
2009
Omphalotus olearius
brenda
Zeng, X.F.; Li, W.W.; Fan, H.J.; Wang, X.Y.; Ji, P.; Wang, Z.R.; Ma, S.; Li, L.L.; Ma, X.F.; Yang, S.Y.
Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain
Bioorg. Med. Chem. Lett.
21
4742-4744
2011
Homo sapiens (P49327)
brenda
Razani, B.; Zhang, H.; Schulze, P.C.; Schilling, J.D.; Verbsky, J.; Lodhi, I.J.; Topkara, V.K.; Feng, C.; Coleman, T.; Kovacs, A.; Kelly, D.P.; Saffitz, J.E.; Dorn, G.W.; Nichols, C.G.; Semenkovich, C.F.
Fatty acid synthase modulates homeostatic responses to myocardial stress
J. Biol. Chem.
286
30949-30961
2011
Mus musculus
brenda
Oh, J.; Hwang, I.H.; Hong, C.E.; Lyu, S.Y.; Na, M.
Inhibition of fatty acid synthase by ginkgolic acids from the leaves of Ginkgo biloba and their cytotoxic activity
J. Enzyme Inhib. Med. Chem.
28
565-568
2013
Gallus gallus, Homo sapiens
brenda
Pappenberger, G.; Benz, J.; Gsell, B.; Hennig, M.; Ruf, A.; Stihle, M.; Thoma, R.; Rudolph, M.G.
Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design
J. Mol. Biol.
397
508-519
2010
Homo sapiens (P49327)
brenda
Gipson, P.; Mills, D.J.; Wouts, R.; Grininger, M.; Vonck, J.; Kuehlbrandt, W.
Direct structural insight into the substrate-shuttling mechanism of yeast fatty acid synthase by electron cryomicroscopy
Proc. Natl. Acad. Sci. USA
107
9164-9169
2010
Saccharomyces cerevisiae
brenda
Yu, X.; Liu, T.; Zhu, F.; Khosla, C.
In vitro reconstitution and steady-state analysis of the fatty acid synthase from Escherichia coli
Proc. Natl. Acad. Sci. USA
108
18643-18648
2011
Escherichia coli
brenda
Zhao, W.; Wang, Y.; Hao, W.; Zhao, M.; Peng, S.
In vitro inhibition of fatty acid synthase by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose plays a vital role in anti-tumour activity
Biochem. Biophys. Res. Commun.
445
346-351
2014
Homo sapiens
brenda
Cui, W.; Liang, Y.; Tian, W.; Ji, M.; Ma, X.
Regulating effect of beta-ketoacyl synthase domain of fatty acid synthase on fatty acyl chain length in de novo fatty acid synthesis
Biochim. Biophys. Acta
1861
149-155
2016
Homo sapiens
brenda
Liang, Y.; Tian, W.; Ma, X.
Inhibitory effects of grape skin extract and resveratrol on fatty acid synthase
BMC Complement. Altern. Med.
13
361
2013
Gallus gallus
brenda
Hopperton, K.E.; Duncan, R.E.; Bazinet, R.P.; Archer, M.C.
Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity
Exp. Cell Res.
320
302-310
2014
Homo sapiens
brenda
Hopcroft, P.; Fisher, D.
Development of a medium-throughput targeted LCMS assay to detect endogenous cellular levels of malonyl-CoA to screen fatty acid synthase inhibitors
J. Biomol. Screen.
21
111-116
2016
Homo sapiens
brenda
Liu, H.; Wu, X.; Dong, Z.; Luo, Z.; Zhao, Z.; Xu, Y.; Zhang, J.T.
Fatty acid synthase causes drug resistance by inhibiting TNF-alpha and ceramide production
J. Lipid Res.
54
776-785
2013
Homo sapiens
brenda
Bollu, L.R.; Katreddy, R.R.; Blessing, A.M.; Pham, N.; Zheng, B.; Wu, X.; Weihua, Z.
Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
Oncotarget
6
34992-35003
2015
Homo sapiens
brenda
Wang, Y.; Nie, F.; Ouyang, J.; Wang, X.; Ma, X.
Inhibitory effects of sea buckthorn procyanidins on fatty acid synthase and MDA-MB-231 cells
Tumour Biol.
35
9563-9569
2014
Homo sapiens
brenda
Rittner, A.; Paithankar, K.S.; Huu, K.V.; Grininger, M.
Characterization of the polyspecific transferase of murine type I fatty acid synthase (FAS) and implications for polyketide synthase (PKS) engineering
ACS Chem. Biol.
13
723-732
2018
Mus musculus (P19096)
brenda
Topolska, M.; Martinez-Montanes, F.; Ejsing, C.S.
Topolska, M.; Martixadnez-Montanes, F.; Ejsing, C. A simple and direct assay for monitoring fatty acid synthase activity and product-specificity by high-resolution mass spectrometry
Biomolecules
10
118
2020
Bos taurus (Q71SP7)
brenda
Rossini, E.; Gajewski, J.; Klaus, M.; Hummer, G.; Grininger, M.
Analysis and engineering of substrate shuttling by the acyl carrier protein (ACP) in fatty acid synthases (FASs)
Chem. Commun. (Camb.)
54
11606-11609
2018
Corynebacterium ammoniagenes
brenda
Crous-Maso, J.; Palomeras, S.; Relat, J.; Camo, C.; Martinez-Garza, U.; Planas, M.; Feliu, L.; Puig, T.
(-)-Epigallocatechin 3-gallate synthetic analogues inhibit fatty acid synthase and show anticancer activity in triple negative breast cancer
Molecules
23
1160
2018
Homo sapiens (P49327)
brenda
Rittner, A.; Paithankar, K.S.; Drexler, D.J.; Himmler, A.; Grininger, M.
Probing the modularity of megasynthases by rational engineering of a fatty acid synthase Type I
Protein Sci.
28
414-428
2019
Mus musculus (P19096)
brenda